The ability to position its latest Food and Drug Administration-approved drug so that it doesn’t steal away market share from its existing therapies is critical to Gilead Sciences (NASDAQ: GILD) delivering sales growth this year. Can Gilead Sciences’ Epclusa reshape hepatitis C treatment without derailing sales already being generated by Gilead’s top sellers, Sovaldi and Harvoni?